These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

611 related items for PubMed ID: 25877327

  • 1. The hallucinogenic world of tryptamines: an updated review.
    Araújo AM, Carvalho F, Bastos Mde L, Guedes de Pinho P, Carvalho M.
    Arch Toxicol; 2015 Aug; 89(8):1151-73. PubMed ID: 25877327
    [Abstract] [Full Text] [Related]

  • 2. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
    Rickli A, Moning OD, Hoener MC, Liechti ME.
    Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
    [Abstract] [Full Text] [Related]

  • 3. Abuse liability profile of three substituted tryptamines.
    Gatch MB, Forster MJ, Janowsky A, Eshleman AJ.
    J Pharmacol Exp Ther; 2011 Jul; 338(1):280-9. PubMed ID: 21474568
    [Abstract] [Full Text] [Related]

  • 4. Clinical toxicology of newer recreational drugs.
    Hill SL, Thomas SH.
    Clin Toxicol (Phila); 2011 Oct; 49(8):705-19. PubMed ID: 21970769
    [Abstract] [Full Text] [Related]

  • 5. The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice.
    Carbonaro TM, Eshleman AJ, Forster MJ, Cheng K, Rice KC, Gatch MB.
    Psychopharmacology (Berl); 2015 Jan; 232(1):275-84. PubMed ID: 24985890
    [Abstract] [Full Text] [Related]

  • 6. Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines.
    Winter JC.
    Psychopharmacology (Berl); 2009 Apr; 203(2):251-63. PubMed ID: 18979087
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties.
    Puigseslloses P, Nadal-Gratacós N, Ketsela G, Weiss N, Berzosa X, Estrada-Tejedor R, Islam MN, Holy M, Niello M, Pubill D, Camarasa J, Escubedo E, Sitte HH, López-Arnau R.
    Mol Psychiatry; 2024 Aug; 29(8):2346-2358. PubMed ID: 38486047
    [Abstract] [Full Text] [Related]

  • 10. Hypothetical biosynthetic pathways of pharmaceutically potential hallucinogenic metabolites in Myristicaceae, mechanistic convergence and co-evolutionary trends in plants and humans.
    Barman R, Kumar Bora P, Saikia J, Konwar P, Sarkar A, Kemprai P, Proteem Saikia S, Haldar S, Slater A, Banik D.
    Phytochemistry; 2024 Feb; 218():113928. PubMed ID: 38035973
    [Abstract] [Full Text] [Related]

  • 11. Recreational use, analysis and toxicity of tryptamines.
    Tittarelli R, Mannocchi G, Pantano F, Romolo FS.
    Curr Neuropharmacol; 2015 Jan; 13(1):26-46. PubMed ID: 26074742
    [Abstract] [Full Text] [Related]

  • 12. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT.
    Jovel A, Felthous A, Bhattacharyya A.
    J Forensic Sci; 2014 May; 59(3):844-6. PubMed ID: 24329118
    [Abstract] [Full Text] [Related]

  • 13. Pharmacologic Similarities and Differences Among Hallucinogens.
    Waters K.
    J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S100-S113. PubMed ID: 34396556
    [Abstract] [Full Text] [Related]

  • 14. Pharmaco-toxicological effects of the novel tryptamine hallucinogen 5-MeO-MiPT on motor, sensorimotor, physiological, and cardiorespiratory parameters in mice-from a human poisoning case to the preclinical evidence.
    Bassi M, Bilel S, Tirri M, Corli G, Di Rosa F, Gregori A, Alkilany AM, Rachid O, Roda E, Zauli G, Locatelli CA, Marti M.
    Psychopharmacology (Berl); 2024 Mar; 241(3):489-511. PubMed ID: 38214743
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin.
    Sherwood AM, Halberstadt AL, Klein AK, McCorvy JD, Kaylo KW, Kargbo RB, Meisenheimer P.
    J Nat Prod; 2020 Feb 28; 83(2):461-467. PubMed ID: 32077284
    [Abstract] [Full Text] [Related]

  • 16. Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
    Warren AL, Lankri D, Cunningham MJ, Serrano IC, Parise LF, Kruegel AC, Duggan P, Zilberg G, Capper MJ, Havel V, Russo SJ, Sames D, Wacker D.
    Nature; 2024 Jun 28; 630(8015):237-246. PubMed ID: 38720072
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca.
    McKenna D, Riba J.
    Curr Top Behav Neurosci; 2018 Jun 28; 36():283-311. PubMed ID: 28401525
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.